Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
Lepe, José Antonio; García-Cabrera, Emilio; Gil-Navarro, María Victoria; Aznar, Javier.
Rev Esp Quimioter
; 25(2): 134-8, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22707102
Prevalence of hypermutators among clinical Acinetobacter baumannii isolates.
Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.
In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene.
In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France.
Cerebrospinal fluid penetration of very high-dose meropenem: a case report.
Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia.
Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin.